CN1714796A - Medicine for treating cardiocerebral vascular diseases - Google Patents
Medicine for treating cardiocerebral vascular diseases Download PDFInfo
- Publication number
- CN1714796A CN1714796A CN 200410019851 CN200410019851A CN1714796A CN 1714796 A CN1714796 A CN 1714796A CN 200410019851 CN200410019851 CN 200410019851 CN 200410019851 A CN200410019851 A CN 200410019851A CN 1714796 A CN1714796 A CN 1714796A
- Authority
- CN
- China
- Prior art keywords
- adjuvant
- starch
- breviscapine
- medicine
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 143
- 229940079593 drug Drugs 0.000 title claims abstract description 65
- 208000019553 vascular disease Diseases 0.000 title abstract description 3
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims abstract description 103
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims abstract description 103
- 239000002671 adjuvant Substances 0.000 claims description 133
- 239000006187 pill Substances 0.000 claims description 121
- 239000000203 mixture Substances 0.000 claims description 105
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 57
- 239000000758 substrate Substances 0.000 claims description 54
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 53
- 239000000811 xylitol Substances 0.000 claims description 53
- 235000010447 xylitol Nutrition 0.000 claims description 53
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 53
- 229960002675 xylitol Drugs 0.000 claims description 53
- 229920002472 Starch Polymers 0.000 claims description 52
- 239000008107 starch Substances 0.000 claims description 52
- 235000019698 starch Nutrition 0.000 claims description 52
- 238000002156 mixing Methods 0.000 claims description 41
- 238000002844 melting Methods 0.000 claims description 38
- 230000008018 melting Effects 0.000 claims description 38
- 238000002360 preparation method Methods 0.000 claims description 38
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 36
- 238000010438 heat treatment Methods 0.000 claims description 36
- 239000008101 lactose Substances 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 34
- 238000009413 insulation Methods 0.000 claims description 33
- 241000196324 Embryophyta Species 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 26
- 229920002545 silicone oil Polymers 0.000 claims description 26
- 235000010489 acacia gum Nutrition 0.000 claims description 25
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 25
- 239000002826 coolant Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 23
- 238000012856 packing Methods 0.000 claims description 23
- 239000000945 filler Substances 0.000 claims description 18
- 229920000881 Modified starch Polymers 0.000 claims description 16
- 241001597008 Nomeidae Species 0.000 claims description 16
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 16
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 16
- -1 hydroxypropyl Chemical group 0.000 claims description 16
- 229940057995 liquid paraffin Drugs 0.000 claims description 16
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 16
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 229920001817 Agar Polymers 0.000 claims description 14
- 239000008272 agar Substances 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 14
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 229920000609 methyl cellulose Polymers 0.000 claims description 12
- 239000001923 methylcellulose Substances 0.000 claims description 12
- 235000010981 methylcellulose Nutrition 0.000 claims description 12
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- 239000004375 Dextrin Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 10
- 235000010443 alginic acid Nutrition 0.000 claims description 10
- 239000000783 alginic acid Substances 0.000 claims description 10
- 229920000615 alginic acid Polymers 0.000 claims description 10
- 229960001126 alginic acid Drugs 0.000 claims description 10
- 150000004781 alginic acids Chemical class 0.000 claims description 10
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 10
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- 235000019425 dextrin Nutrition 0.000 claims description 10
- 229920000936 Agarose Polymers 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 8
- 235000010418 carrageenan Nutrition 0.000 claims description 8
- 229920001525 carrageenan Polymers 0.000 claims description 8
- 235000010980 cellulose Nutrition 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940032147 starch Drugs 0.000 claims description 7
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 6
- 229930091371 Fructose Natural products 0.000 claims description 6
- 239000005715 Fructose Substances 0.000 claims description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 6
- 235000001727 glucose Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000000905 isomalt Substances 0.000 claims description 6
- 235000010439 isomalt Nutrition 0.000 claims description 6
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001630 malic acid Substances 0.000 claims description 6
- 235000011090 malic acid Nutrition 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 244000286663 Ficus elastica Species 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 4
- 239000004368 Modified starch Substances 0.000 claims description 4
- 240000004584 Tamarindus indica Species 0.000 claims description 4
- 235000004298 Tamarindus indica Nutrition 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 229920000591 gum Polymers 0.000 claims description 4
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 4
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 229960000292 pectin Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 235000002639 sodium chloride Nutrition 0.000 claims description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229960001947 tripalmitin Drugs 0.000 claims description 2
- 244000275012 Sesbania cannabina Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 21
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000002490 cerebral effect Effects 0.000 abstract description 2
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 239000003292 glue Substances 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 208000026106 cerebrovascular disease Diseases 0.000 description 10
- 230000002526 effect on cardiovascular system Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 241000219782 Sesbania Species 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000006225 natural substrate Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000035943 smell Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241001013934 Erigeron breviscapus Species 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003578 releasing effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 241000132521 Erigeron Species 0.000 description 1
- 241001411320 Eriogonum inflatum Species 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a kind of medicine prepared with breviscapine and proper amount of supplementary material for treating cardiac and cerebral vascular diseases. Compared with available similar medicines, the medicine of the present invention has high safety, lower toxic side effect and good taste.
Description
Technical field
The present invention relates to field of medicaments, particularly, relating to Chinese medicine is the pharmaceutical preparation of the treatment cardiovascular and cerebrovascular disease made of raw material.
Background technology
Cardiovascular and cerebrovascular disease is listed as first of each big disease, serious harm human body health, and the sequela that is caused is also brought very big misery to patient and family members, becomes the social problem of a worth extensive concern.Countries in the world medicine worker constantly studies, develops the prevention and the rehabilitation medicine of medicine, the especially cardiovascular and cerebrovascular disease of cardiovascular and cerebrovascular disease, and the cardiovascular and cerebrovascular disease patient can effectively be treated.Therefore, the development of cardiovascular and cerebrovascular diseases medicine is not only being healed the wounded and rescue the dying, is being had extremely important social meaning aspect the rehabilitation, but also has remarkable economic efficiency.
Breviscapine (Brceviscapini), be yellow powder, dissolve in aqueous alkali, be slightly soluble in methanol, water insoluble, chloroform etc., have and more obviously improve the brain blood circulation, increase cerebrovascular flow, reduce the effect of vascular resistance and anti-platelet aggregation, evidence: better to paralysis and the paralysis of the sequela due to cerebral hemorrhage curative effect due to the obliterated cerebral vascular disease, make the breviscapine dispersible tablet with breviscapine at present, erigeron breviscapus powder injection, erigeron breviscapus slow release capsule, Erigreron breviscapus extract controlled releasing tablet, erigeron breviscopus element soft capsule, dosage form such as breviscapine infusion preparation and breviscapine drop pills.
The synthetic chemical substance commonly used as modern medicine spreaded all over each corner of human lives, chemical synthetic drug becomes the main flow of medicine, yet, appearance along with multiple difficult serious symptom miscellaneous diseases, western medical treatment presents imperfect, the human lives and the healthy reality and the up-to-date successes achieved in research have all proposed query to this situation, particularly along with the continuous appearance of chemical drugs toxic and side effects, the change of spectrum of disease and conversion of medical, make modern medicine be subjected to unprecedented challenge, and people also place hope in the application and development of traditional medicine on gradually.Advocate back to nature, pay attention to plant amedica use, hanker after traditional remedies, the trend of advocating natural drug forms, making full use of natural materials is human best selections.
At present, in the world, natural drug all has certain market, along with people increasing and the aging of population to the health requirements level of understanding, sub-health stateization, people thirst for back to nature more, the problem of utilize the high Drug therapy of pure natural degree, preventing some chemical synthetic drugs cann't be solved, so the background that exceeds its original traditional national culture has been expanded in the application of natural plant.From natural drug, seek the little and inexpensive medicine of side effect and become the target that countries in the world pharmaceutical manufacturer is chased.The European Community has carried out unified legislation to medical herbs, state medical herbs status such as Canada and Australia have legalized, U.S. government has also drafted the plant amedica management method, the compound recipe mix preparation that begins to accept natural drug is as curative, and these provide good international environment for Chinese medicine enters international medical market as curative.On the other hand, along with the quickening of global economic integration progress, particularly China becomes a full member of WTO, and Chinese Medicine market incorporates the breadth and depth of international medical big market and will further aggravate.Face the enormous impact of Asian countries's traditional medicine product such as the keen competition of powerful transnational medical group and Japan, Korea S, India, Thailand and European countries' plant amedica such as Germany, France, numerous products that China's Chinese medicine produces are owing to still can not meet the standard of international medical market and requirement and being kept outside of the door.
Expansion and human back to nature requirement along with the market global range, use the low medicine of toxic and side effects, especially pure natural medical more and more becomes people's first-selection, dropping pill formulation be a kind of have efficient, quick-acting new medicine preparations, it has overcome the shortcoming and deficiency of Chinese medicine preparation in the past, but present dropping pill formulation generally faces following problem: 1, drop pill adjuvant pure natural degree is not high: at present, drop pill substrate adjuvant mostly is synthetic, natural degree is lower, the searching of new alternative substrate adjuvant, the searching of the alternative substrate adjuvant that particularly natural degree is high and preparation technology thereof determine, it is again very difficult thing, because the required preparation condition of at present common possible natural substrates adjuvant succedaneum is very harsh, it all is to influence the key that drop pill prepares molding that adjuvant temperature and drop pill thereof drip the system condition.The too high then viscosity of adjuvant melt temperature is low, and poor plasticity is though the adjuvant melt temperature is crossed lowplastcity by force, but drop pill has shortcomings such as easily sticking ball, distortion, therefore, seek pure natural degree height, and the adjuvant that is suitable for substituting existing drop pill substrate is a very job of hardships.2, the drop pill outlet encounters problems: along with expanding economy, more and more internationalize in market, China is also just making great efforts to adapt to this trend, present Chinese medicine dripping pills preparation as health food, successful export to many countries, but also face many problems at present, because different countries is different to the approval of the selected adjuvant of Chinese medicine dropping pill formulation, especially industrial flourishing Europe, more strict to food adjuvant and medical auxiliary materials, and as the selected chemosynthesis adjuvant (as Polyethylene Glycol) of the dropping pill formulation of health food outlet not in the catalogue of some national food additive, it is very unfavorable that this moves towards the international market to the Chinese medicine dropping pill formulation, becomes the stumbling-block that Chinese medicine enters the international market, therefore, seek the new of one or more, can be particularly important, also very urgent for the substrate adjuvant that the international market is accepted.3, the shortcoming of mouthfeel and onset speed: the mouthfeel of Chinese medicine and preparation thereof is relatively poor to be the big characteristics of one, people when taking some drugs to the frightened of disagreeable taste that medicine had even be better than fear far away to disease, What is more, some patients are because can not overcome the poor taste of Chinese medicine or its preparation or abnormal smells from the patient and abandon the treatment of Chinese medicine, though can improve mouthfeel as medicine being made capsule or sugar coated tablet, reducing stimulates, but disintegration rate prolongs, be unfavorable for the rapid onset of medicine, to some disease, particularly need the disease of the rapid onset of medicine inapplicable.4, the preparation process difficulty of drop pill suitability for industrialized production: in the replacement process of dropping pill formulation adjuvant, determining of the preparation process of its suitability for industrialized production is very difficult something, as the ratio of the melt temperature of substrate adjuvant, the proportioning of dripping system temperature, adjuvant and medicine, dropper bore, condensing agent etc. all are the factors that influence drop pill, therefore, the replacement of substrate and to be suitable for suitability for industrialized production be a job consuming time, as to expend substantial contribution.
In order to change drop pill substrate adjuvant for a long time based on the situation of chemosynthesis adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and can not satisfy more and more that people require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect; Also can solve some problems that Chinese medicine preparation, particularly dropping pill formulation are run in exit procedure, strengthen the competitiveness of international market; The present invention has invented the pure Chinese medicine dripping pills preparation that a kind of toxic and side effects is low, evident in efficacy, moderate, adapt to industrialized great production by a large amount of tests and the research of preparation process.
Summary of the invention
The medicine that the purpose of this invention is to provide a kind of treatment cardiovascular and cerebrovascular disease with new type natural substrate adjuvant preparation.
Another object of the present invention provides a kind of preparation method for the treatment of the cardiovascular and cerebrovascular diseases medicament preparation.
The present invention is the new pharmacological action that the qi-blood relationship theory learned according to Chinese traditional medicine and modern medicine are found various institutes of Chinese materia medica, according to the principle of " symptomatic treatment in acute condition, radical treatment in chronic case ", set upright based on reinforcing, " lead to " and just must not hinder, " benefit " must not be detained, treating both the principal and secondary aspects of a disease.The medicine of producing according to this method has late result again, and finally reaches the healing purpose the existing short term effect of the treatment of coronary heart disease, and generation without any side effects.The selected substrate adjuvant of the present invention is resulting by a large amount of tests, it is little to have molecular weight, soluble in water, and molten diffusing speed is faster, pure natural degree height, toxic and side effects is lower, and can reduce the medicine irritation abnormal smells from the patient, has the oral cavity of improvement acid-base value during the buccal of oral cavity, improve the characteristics of oral cavity smell, the used substrate adjuvant of the present invention is the agent of food sedan-chair flavor, takes that mouthfeel is good, the acceptant characteristics of patient, is the direction of following substrate adjuvant development.
The consumption of drug component of the present invention and the selection of adjuvant thereof also grope to sum up to draw through the inventor in a large number, each amounts of components all has curative effect preferably in following ranges: breviscapine, appropriate amount of auxiliary materials is made, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from the natural adjuvant of following one or more plant origins: erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural adjuvant of following one or more plant origins: starch and derivant thereof, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose;
Preferred drug component consumption of the present invention and adjuvant thereof be chosen as 0.2～48 part of breviscapine, 4.8～60 parts of adjuvants are made, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from natural adjuvant erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose of following one or more plant origins etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural supplementary product starch of following one or more plant origins and derivant, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose;
Further preferred drug component consumption of the present invention and adjuvant thereof be chosen as 0.6～1.5 part of breviscapine, 2.0～20 parts of adjuvants are made, filler adjuvant wherein is selected from following one or more the natural adjuvant sorbitol of plant origin, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant pregelatinized Starch of plant origin, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose;
Further preferred drug component consumption of the present invention and adjuvant thereof be chosen as 0.8～1.2 part of breviscapine, 2.3～15 parts of adjuvants are made, filler adjuvant wherein is selected from following one or more the natural adjuvant sorbitol of plant origin, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant pregelatinized Starch of plant origin, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose;
Further preferred drug component consumption of the present invention and adjuvant thereof be chosen as 1 part of breviscapine, 3～10 parts of adjuvants are made, filler adjuvant wherein is selected from following one or more the natural adjuvant sorbitol of plant origin, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant pregelatinized Starch of plant origin, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose;
Best drug component consumption of the present invention and adjuvant thereof be chosen as 1 part of breviscapine, 3～10 parts of adjuvants are made, filler adjuvant wherein is selected from following one or more the natural adjuvant xylitol of plant origin, lactose; Plasticity substrate wherein is selected from following one or more the natural supplementary product starch of plant origin, arabic gum.
Can also contain chemosynthesis adjuvant and animal origin adjuvant in the above-mentioned adjuvant, wherein filler comprises phenylglycol, hexadecanol, octadecanol, sodium stearate, tristerin, tripalmitin, carbamide, polyoxyethylene monostearate, polyoxyethylene alkyl ether; Wherein plasticity substrate comprises polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, gelatin.
At ratio of adjuvant molding is found in the sex research, in the combination of xylitol and starch, lactose and starch, xylitol and arabic gum, low melting point substrate adjuvant is 1: 0～1: 1.5 with the ratio of the weight of plasticity substrate adjuvant, be preferably 1: 0.1～1: 0.9, the best is 1: 0.1～1: 0.5.Low melting point substrate adjuvant of being formed within this scope and plasticity substrate adjuvant, the drug matrices fused solution all can ooze, and can condensation.Specific to each combination, xylitol is preferably 1: 0.2 with the ratio of the weight of starch～1: 0.3, and lactose is preferably 1: 0.2 with the ratio of the weight of starch～1: 0.3, and the ratio of the weight of xylitol and arabic gum is preferably 1: 0.2～and 1: 0.4.Find that in the research of temperature temperature is big especially to the influence of drop pill mouldability to the influence of drop pill mouldability, when temperature is too low, owing to the too big effect that oozes that influences drop pill of viscosity of substrate, when temperature is too high, not condensation of drop pill.Find that mixing time can have influence on the mouldability of drop pill in mixing time in to the sex research of drop pill molding, mixing time is too short, and mobile poor, influence oozes, and mixing time is oversize, influences the condensation of drop pill.Dripping under the system temperature, mixing time in 1～120 minute all can, suitable mixing time was at 10～30 minutes.Consider that mixing time can not be too short in the suitability for industrialized production, adopt the method that low temperature stirs for a long time, high temperature drips system.Find that in the research of dropper bore to the influence of drop pill particle diameter the dropper bore influences the size of drop pill and the flowability of fusion substrate, the system effect is dripped in influence.Drop pill diminishes and diminishes along with bore, but after 1.4 millimeters, along with the bore change of size that diminishes is not obvious, but the matrix flow reduction, system is dripped in influence.
So in the preparation method of preparation, medicine mixes mixing time with the substrate adjuvant be 10～30 minutes; The mixed heating and melting temperature of medicine and substrate adjuvant is 45～115 ℃, dripping the system temperature is 45～95 ℃, and liquid coolant is liquid paraffin, methyl-silicone oil or vegetable oil (Oleum Glycines, Semen Ricini wet goods), and the temperature of liquid coolant is-20～25 ℃, dropper mouth internal diameter is 1.0～4.0 millimeters; Preferred heating and melting temperature is 60～85 ℃, and dripping a system temperature is 60～85 ℃, and condensing agent is liquid paraffin, methyl-silicone oil, and the condensing agent temperature is 0～18 ℃, and the dropper bore is 1.1～3.5 millimeters, and the difference of dropper mouth external diameter and internal diameter is less for well; Best heating and melting temperature is that to make temperature be that 64 ℃, dropper bore are that 1.2～2.5 millimeters, condensing agent are 0 ℃ methyl-silicone oil to 64 ℃, droplet.
The substrate adjuvant of the best of the present invention is xylitol and starch, and xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or be xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
Xylitol is a kind of natural plant sweetening agent, approve through World Health Organization (WHO), xylitol is a kind of safest sweeting agent, countries in the world are extensive use of in fields such as food and oral-cavity articles, xylitol enters the help that need not insulin in the cell, when sugar utilizes obstacle, can not cause blood sugar increasing yet, can improve diabetics symptom, have the ketoplastic effect of powerful inhibition, can promote the generation of liver glycogen, directly infiltrate the Developmental and Metabolic Disorder that tissue is participated in metabolism, can be corrected protein, fat and steroid; Xylose is the internal metabolism intermediate product, and body has higher toleration to it.Clinical practice proves: the highest oral dosis tolerata can reach 220g every day, and intravenous drip every day can reach 100g.The oral 25700mg/Kg of median lethal dose(LD 50) (LD50) mice, quiet notes 6400mg/Kg, the quiet notes of rat 6200mg/Kg.
Medicine mesostroma adjuvant of the present invention and amount of drug are than can being the scope that allows on the galenic pharmacy, medicine described here can be that crude drug also can be the effective ingredient extract, in order to adapt to industrialized great production, used medicine material is a breviscapine among the present invention.
Medicine of the present invention can adopt the preparation of Chinese medicine preparation conventional method, but in order to make each crude drug of this medicine better bring into play drug effect, the present invention adopts preparation method as follows, but this can not limit protection scope of the present invention.
The preparation method of medicine of the present invention is as follows:
(a) by proportioning take by weighing each crude drug breviscapine, appropriate amount of auxiliary materials is standby;
(b) in appropriate amount of auxiliary materials, add breviscapine, fully mix, be prepared into the oral formulations that allows on the pharmaceutics according to the pharmaceutics preparation method, promptly.
Preferred manufacturing procedure comprises the following steps:
(a) by proportioning take by weighing 0.2～48 part of breviscapine of each crude drug, 4.8～60 parts of adjuvants are standby;
(b) in appropriate amount of auxiliary materials, add breviscapine, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, drip and make ball, promptly.
Further preferred manufacturing procedure comprises the following steps:
(a) by proportioning take by weighing 0.6～1.5 part of breviscapine of each crude drug, 2.0～20 parts of adjuvants are standby;
(b) in adjuvant, add the said extracted thing, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 0～18 ℃ the liquid paraffin, methyl-silicone oil, drip and make ball, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Further preferred manufacturing procedure comprises the following steps:
(a) by proportioning take by weighing 0.8～1.2 part of breviscapine of each crude drug, 2.3～15 parts of adjuvants are standby;
(b) in adjuvant, add the said extracted thing, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 0～18 ℃ the liquid paraffin, methyl-silicone oil, drip and make ball, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Best preparation method comprises the following steps:
(a) by proportioning take by weighing 1 part of breviscapine of each crude drug, 3～10 parts of adjuvants are standby;
(b) get appropriate amount of auxiliary materials, add the active component of method for preparing, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, drip and make ball, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
The best preparation method of medicine of the present invention is:
(a) by proportioning take by weighing 1 part of breviscapine of each crude drug, 3～10 parts of adjuvants are standby;
(b) get 3～10 parts of xylitol and starch, xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or 3～10 parts of lactose and starch, lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch; Or 3～10 parts of xylitol and arabic gum, the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4 a adjuvant, adds the active component of method for preparing, fully mix, mixture stirs at 64 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.2～2.5 millimeters at 64 ℃ of temperature following system, dropper bore, splashes in 0 ℃ the methyl-silicone oil, drip and make ball, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
Medicine of the present invention can be determined usage and dosage according to patient's situation in use, but every day 1-3 time, and every day, each crude drug consumption was as the criterion with the state-promulgated pharmacopoeia dosage, was no more than the pharmacopeia ormal weight.
The drop pill that the present invention is prepared, conventional drop pill advantage is simple as preparing except having, steady quality, can make liquid medicine solidification, convenient drug administration, efficient, quick-acting, its biggest advantage is:
1, the selected adjuvant pure natural of the present invention degree height: the substrate adjuvant that employed substrate adjuvant derives from natural plants or originates based on natural plants among the present invention, selected substrate adjuvant is xylitol and starch or lactose and starch or xylitol and arabic gum, this substrate adjuvant has pure natural degree height, toxic and side effects is low, mouthfeel is good, dissolve scattered time limit is short, rapid-action, it is a kind of new medium adjuvant, can be used for substituting present chemosynthesis adjuvant, the drop pill made from this kind adjuvant, it is low to solve the pure natural degree that present drop pill substrate faced, and more and more can not satisfy people and require back to nature, take low toxicity, the problem of the pure natural medical that has no side effect.
2, some problems in the outlet of solution Chinese medicine: medicine of the present invention also can solve Chinese medicine preparation, some problems of in exit procedure, being run into of dropping pill formulation particularly, solve because different countries, especially the European countries of industry prosperity are to the difference identification of the selected adjuvant of Chinese medicine dropping pill formulation, overcome as the selected adjuvant Polyethylene Glycol of the dropping pill formulation of the health food outlet defective in some national food additive catalogue not, improve the Chinese medicine dripping pills preparation and move towards the international market, strengthen the competitiveness of international market.
3, solve the relatively poor problem of dropping pill formulation taste and further improve drug effect speed (dissolve scattered time limit): the medicinal dropping ball made from this kind substrate adjuvant of the present invention, can improve Chinese medicine preparation, the particularly present not good shortcoming of dropping pill formulation taste, improve mouthfeel, more easy for patients to accept, and the drop pill that adopts the selected adjuvant of medicine of the present invention to make has shorter dissolve scattered time limit, making drug effect faster, is the medicine that coronary heart disease, angina pectoris, myocardial ischemia are treated in a kind of onset faster.
4, higher safety and solve some problems in the drop pill storage process: the selected substrate of the present invention is not only additive, nutrient commonly used in the food industry, and can do medicinal, but do not see that it uses as the drug matrices adjuvant, therefore, with regard to substrate, be perfectly safe, have no side effect, a large amount of evidences, the drop pill made from this adjuvant can reduce effective ingredient separating out in storage process, the sticking ball of drop pill, easy shortcomings such as moisture absorption deliquescing, but the big production of suitability for industrialized.
The present invention is under instruction of Chinese Medicine theory, preparation technology's test that process is a large amount of and pharmacology, the resulting preparation of pharmacodynamics test.The present invention is evident in efficacy, has the effect of expelling cold and relieving exterior syndrome, expelling wind and removing dampness, activating blood circulation to dissipate blood stasis, dredge the meridian passage, anti-inflammatory analgetic.Herba Erigerontis is mainly used in the treatment of ischemic cerebrocardiac disease clinically at present, has the curative effect of highly significant for cerebral infarction especially.Reasonable recipe of the present invention, poisonous side effect of medicine is low, overcome that western medicine coronary heart disease toxic and side effects is big, expense is high, the Chinese medicine curative effect is low, flavour of a drug are many, the shortcoming of incompatibility large-scale production, is the medicine of the definite treatment coronary heart disease of a kind of economy, material benefit, curative effect.
In order to understand the present invention better, below with test explanation advantages of the present invention such as the present invention's's (following the present invention is called breviscapine drop pills) dissolve scattered time limit, weight differential, drop pill soft durometer, the sticking balls of drop pill.
Test example 1: dissolve scattered time limit, weight differential contrast experiment's example
In vitro tests
The present invention be that the breviscapine drop pills that adjuvant is made compares with the Polyethylene Glycol, by measuring dissolve scattered time limit, investigate its good releasing effect; By measuring indexs such as the ball method of double differences is different, investigate whether it ripe in preparation technology, whether be fit to suitability for industrialized production.
1. test medication: the new substrate breviscapine drop pills of the present invention (newly), Tianjin Tasly Pharmaceutical Co., Ltd provides, and is the breviscapine drop pills (old) that adjuvant is made with the Polyethylene Glycol.
2. method and result:
Dissolve scattered time limit: by " method is measured under this item of Chinese pharmacopoeia; The ball method of double differences is different: by " method is measured under this item of Chinese pharmacopoeia.Result of the test sees Table 1.
Three batches of breviscapine drop pills made from the new medium adjuvant of table 1 (newly) with Polyethylene Glycol be breviscapine drop pills (old) dissolve scattered time limit made of main adjuvant, weight differential relatively
| 0 month | January | February | March | June | December | 18 months | ||
| 1 batch | Criterion | The result | ||||||
| Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | |
| Dissolve scattered time limit (newly) (30 minutes) (old) | 2′10″ 5′19″ | 2′14″ 5′17″ | 2′15″ 5′14″ | 2′14″ 5′27″ | 2′18″ 5′31″ | 2′18″ 5′30″ | 2′20″ 5′35″ | |
| 2 batches | Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (newly) (30 minutes) (old) | 2′9″ 5′18″ | 2′15″ 5′20″ | 2′17″ 5′21″ | 2′18″ 5′23″ | 2′18″ 5′30″ | 2′19″ 5′30″ | 2′21″ 5′32″ | |
| 3 batches | Weight differential (± 15%) | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% | All in 10% |
| Dissolve scattered time limit (newly) (30 minutes) (old) | 2′11″ 5′17″ | 2′14″ 5′16″ | 2′14″ 5′18″ | 2′15″ 5′23″ | 2′17″ 5′24″ | 2′19″ 5′30″ | 2′22″ 5′35″ |
Test data shows, the dissolve scattered time limit of new substrate breviscapine drop pills is lacking of the breviscapine drop pills made of main adjuvant with Polyethylene Glycol, and the ball method of double differences of the breviscapine drop pills that new and old substrate is made is different all to be controlled in the pharmacopeia prescribed limit.Result of the test explanation, the molten diffusing speed of the breviscapine drop pills made from novel adjuvant is faster, is more conducive to medicine and plays a role in the shortest time; The ball method of double differences is different all to be controlled in the pharmacopeia prescribed limit, difference not statistically significant, the alternative present chemosynthesis adjuvant of this natural substrates adjuvant, but suitability for industrialized production.
Test example 2: the present invention with Polyethylene Glycol be the sticking ball comparative observation of the breviscapine drop pills soft durometer made of main adjuvant adjuvant, drop pill
1. test medication: the new substrate breviscapine drop pills of the present invention (newly) is the breviscapine drop pills (old) that main adjuvant is made with Polyethylene Glycol.
2. method and result: three batches of the things of getting it filled are loaded in the porcelain vase respectively, and use the bottle stopper good seal.Putting it into the bottom has in the exsiccator of saturated Nacl (humidity 75%) solution, exsiccator is put into 40 ℃ of drying baker of constant temperature again, and timing sampling is observed situations such as drop pill soft durometer, the sticking ball of drop pill, the results are shown in Table 2.1, table 2.2.
Three batches in table 2.1 is that the breviscapine drop pills reserved sample observing that main adjuvant is made compares with Polyethylene Glycol
| 0 month | January | February | March | June | December | 18 months | ||
| 1 batch | Criterion | The result | ||||||
| Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly | Sticking slightly | |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
| 2 batches | Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
| 3 batches | Sticking ball | Not sticking | Not sticking | Not sticking | Not sticking | Not sticking | Sticking slightly | Sticking slightly |
| Soft durometer | Firmly | Firmly | Firmly | Firmly | Firmly | Harder | Harder | |
Table 2.2: three batches of breviscapine drop pills made from the new medium adjuvant (newly) with Polyethylene Glycol be breviscapine drop pills (old) character observation made of main adjuvant relatively
| 0 month | January | February | March | June | December | 18 months |
| Criterion | The result | |||||||
| 1 batch | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly | Sticking (old) be sticking (newly) slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard (old) hard (newly) | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
| 2 batches | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) glues (newly) slightly slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard (old) hard (newly) | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
| 3 batches | Sticking ball | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) | Sticking (old) do not glue (newly) slightly | Sticking (old) do not glue (newly) slightly | Sticking (old) be sticking (newly) slightly |
| Soft durometer | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | (old) hard (newly) firmly | Hard slightly (old) hard (newly) | Hard slightly (old) be hard (newly) slightly | |
Result of the test shows, the soft durometer of new substrate breviscapine drop pills changes and be that the breviscapine drop pills made of main adjuvant is similar, strong slightly with Polyethylene Glycol; The sticking ball variation of the drop pill of new substrate breviscapine drop pills, firmness change and be that the breviscapine drop pills made of main adjuvant is similar with Polyethylene Glycol.Presentation of results, the sticking ball of the breviscapine drop pills that new, old substrate adjuvant is made changes, firmness change is similar, and the alternative present chemosynthesis adjuvant of this natural substrates adjuvant is described, but suitability for industrialized production.
The specific embodiment
Embodiment 1
(a) get each crude drug breviscapine 0.2g, xylitol 4g, starch 0.8g is standby;
(b) in xylitol and starch mixture, add breviscapine, fully mix, mixture is at 85～115 ℃ of heating and meltings, stir, mixing time is 1～12 minute, insulation, at 45～65 ℃ of temperature following system, dropper bore is 1.40～4.0 millimeters, splash in-20～25 ℃ the methyl-silicone oil, make 1000 drop pill, promptly.
Dissolve scattered time limit sees Table 1.
Embodiment 2
(a) get each crude drug breviscapine 48g, xylitol 50g, starch 10g is standby;
(b) in xylitol and starch mixture, add breviscapine, fully mix, mixture is at 85～115 ℃ of heating and meltings, stir, mixing time is 1～12 minute, insulation, at 50～65 ℃ of temperature following system, dropper bore is 1.40～4.0 millimeters, splash in-20～25 ℃ the liquid paraffin, make 5000 drop pill, promptly.
The sticking ball comparative observation of drop pill soft durometer, drop pill sees Table 2.1, table 2.2
Embodiment 3
(a) get each crude drug breviscapine 4.8g, sorbitol 18.5g, xanthan gum 9.g is standby;
(b) in sorbitol and xanthan gum mixtures, add breviscapine, fully mix, mixture is at 65～85 ℃ of heating and meltings, stir, mixing time is 10～15 minutes, insulation, at 55～68 ℃ of temperature following system, dropper bore is 1.70～3.5 millimeters, splash in 5～15 ℃ the liquid paraffin, make 1000 drop pill, promptly.
Embodiment 4
(a) get each crude drug breviscapine 3g, xylitol 25g, methylcellulose 5g is standby;
(b) in xylitol and methylcellulose mixture, add breviscapine, fully mix, mixture is at 65～85 ℃ of heating and meltings, stir, mixing time is 10 minutes, insulation, at 45～75 ℃ of temperature following system, dropper bore is 1.30～3.0 millimeters, splash in 8～10 ℃ the vegetable oil, make 1000 drop pill, promptly.
Embodiment 5
(a) get each crude drug breviscapine 10g, lactose 17.9g, starch 7.1g is standby;
(b) in lactose and starch mixture, add breviscapine, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 2 ℃ the methyl-silicone oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 6
(a) get each crude drug breviscapine 0.6g, xylitol 26.5g, starch 3.g is standby;
(b) in xylitol and starch mixture, add breviscapine, fully mix, mixture stirs at 80～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.21～3.5 millimeters at 60～65 ℃ of temperature following system, dropper bore, splashes in 5 ℃ the liquid paraffin, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 7
(a) get each crude drug breviscapine 1.5g, xylitol 21.5g, cyclodextrin 6.5g is standby;
(b) in xylitol and cyclodextrin mixt, add breviscapine, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.21～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 5～15 ℃ the methyl-silicone oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 8
(a) get each crude drug breviscapine 1.5g, xylitol 17g, arabic gum 3g is standby;
(b) in xylitol and arabic gum mixture, add breviscapine, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～12 minutes, insulation is 1.6～3.5 millimeters at 60～65 ℃ of temperature following system, dropper bore, splashes in 0～8 ℃ the liquid paraffin, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 9
(a) get each crude drug breviscapine 0.8g, xylitol 13.3g, starch 2.7g is standby;
(b) get xylitol and starch mix homogeneously, add breviscapine, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 10
(a) get each crude drug breviscapine 6g, lactose 12g, starch 6g is standby;
(b) get lactose and starch and mix evenly, add breviscapine, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 11
(a) get each crude drug breviscapine 2g, xylitol 18g, arabic gum 2g is standby;
(b) get xylitol and arabic gum and mix evenly, add breviscapine, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 12
(a) get each crude drug breviscapine 1.2g, xylitol 12.5g, starch 2.5g is standby;
(b) get above-mentioned xylitol and starch and mix, add breviscapine, fully mix, mixture is at 60～69 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 60～69 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 13
(a) get each crude drug breviscapine 12g, xylitol 13.5g, Furcellaran 5.2g is standby;
(b) get xylitol and Furcellaran and mix evenly, add breviscapine, fully mix, mixture is at 55～70 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 58～69 ℃ of temperature following system, dropper bore is 1.21～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 14
(a) it is standby to get each crude drug breviscapine 0.2g, D-ribonic acid-gamma lactone 5g, agar 0.7g;
(b) in D-ribonic acid-gamma lactone and agar mixture, add breviscapine, fully mix, mixture is at 85～115 ℃ of heating and meltings, stir, mixing time is 10～12 minutes, insulation, at 45～65 ℃ of temperature following system, dropper bore is 1.40～4.0 millimeters, splash in-5～5 ℃ the methyl-silicone oil, make 1000 drop pill, promptly.
Embodiment 15
(a) get each crude drug breviscapine 45g, fructose 48g, pectin 12g is standby;
(b) in fructose and pectin mixture, add breviscapine, fully mix, mixture is at 85～115 ℃ of heating and meltings, stir, mixing time is 10～12 minutes, insulation, at 50～65 ℃ of temperature following system, dropper bore is 1.40～4.0 millimeters, splash in-2～5 ℃ the liquid paraffin, make 5000 drop pill, promptly.
Embodiment 16
(a) get each crude drug breviscapine 4.8g, low melting-point agarose 18.4g, microcrystalline Cellulose 9.1g is standby;
(b) in low melting-point agarose and microcrystalline cellulose mixt, add breviscapine, fully mix, mixture is at 65～85 ℃ of heating and meltings, stir, mixing time is 10～15 minutes, insulation, at 55～68 ℃ of temperature following system, dropper bore is 1.70～3.5 millimeters, splash in 5～15 ℃ the liquid paraffin, make 1000 drop pill, promptly.
Embodiment 17
(a) get each crude drug breviscapine 3g, Raffinose 27g, cross-linking sodium carboxymethyl cellulose 4g is standby;
(b) in Raffinose and cross-linking sodium carboxymethyl cellulose mixture, add breviscapine, fully mix, mixture is at 65～85 ℃ of heating and meltings, stir, mixing time is 10 minutes, insulation, at 45～75 ℃ of temperature following system, dropper bore is 1.30～3.0 millimeters, splash in 8～10 ℃ the vegetable oil, make 1000 drop pill, promptly.
Embodiment 18
(a) get each crude drug breviscapine 9g, malic acid 17.9g, hydroxypropyl cellulose 7.8g is standby;
(b) in malic acid and hydroxypropyl cellulose mixture, add breviscapine, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 2 ℃ the methyl-silicone oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 19
(a) get each crude drug breviscapine 0.6g, isomalt 25.5g, microcrystalline Cellulose 3.4g is standby;
(b) in isomalt and microcrystalline cellulose mixt, add breviscapine, fully mix, mixture stirs at 80～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.21～3.5 millimeters at 60～65 ℃ of temperature following system, dropper bore, splashes in 5 ℃ the liquid paraffin, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 20
(a) get each crude drug breviscapine 1.5g, glucose 21.5g, sesbania gum 6.5g is standby;
(b) in glucose and sesbania gum mixture, add breviscapine, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.21～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 10～15 ℃ the methyl-silicone oil, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 21
(a) get each crude drug breviscapine 1.5g, Furcellaran 20g, dextran 2g is standby;
(b) in Furcellaran and dextran mixture, add breviscapine, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～12 minutes, insulation is 1.6～3.5 millimeters at 60～65 ℃ of temperature following system, dropper bore, splashes in 0～8 ℃ the liquid paraffin, make 1000 drop pill, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 22
(a) get each crude drug breviscapine 0.8g, maltose 13.3g, agar 2.7g is standby;
(b) get maltose and agar mix homogeneously, add breviscapine, fully mix, mixture is at 63 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 23
(a) get each crude drug breviscapine 6g, sesbania gum 12g, dextran 6g is standby;
(b) get sesbania gum and dextran and mix evenly, add breviscapine, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Embodiment 24
(a) get each crude drug breviscapine 2g, low melting-point agarose 18g, pregelatinized Starch 2g is standby;
(b) get low melting-point agarose and pregelatinized Starch and mix evenly, add breviscapine, fully mix, mixture is at 65 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 65 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 2 ℃ the methyl-silicone oil, make 1000 drop pill, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Claims (15)
1, a kind of medicine for the treatment of cardiovascular disease, it is characterized in that it is to be made by breviscapine, appropriate amount of auxiliary materials, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from natural adjuvant erythritol, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose of following one or more plant origins etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural supplementary product starch of following one or more plant origins and derivant, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
2, the medicine of treatment cardiovascular disease as claimed in claim 1, it is characterized in that it is by 0.2～48 part of breviscapine, 4.8～60 parts of adjuvants are made, wherein adjuvant comprises filler and plasticity substrate, said filler is selected from the natural adjuvant erythritol of following one or more plant origins, sorbitol, fructose, D-ribonic acid-gamma lactone, arabitol, trehalose, D-ribose, low melting-point agarose, Lac, xylitol, Raffinose, glucose, malic acid, citric acid, isomalt, lactose, maltose etc., and they contain the water of crystallization chemical compound; Said plasticity substrate is selected from the natural supplementary product starch of following one or more plant origins and derivant, cellulose and derivant thereof, arabic gum, dextran, chitin, sesbania gum, carrageenan, Ficus elastica, Furcellaran, tragakanta, carrageenin, tamarind gum, pectin, xanthan gum, alginic acid and salt thereof, dextrin, cyclodextrin, agar, lactose; Described starch and derivant thereof such as pregelatinized Starch, modified starch, hydroxypropyl starch, carboxymethyl starch, described cellulose and derivant thereof such as methylcellulose, microcrystalline Cellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, cross-linking sodium carboxymethyl cellulose, hydroxyethylmethyl-cellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
3, the medicine of treatment cardiovascular disease as claimed in claim 2, it is characterized in that it is to be made by 0.6～1.5 part of breviscapine, 2.0～20 parts of adjuvants, filler adjuvant wherein is selected from following one or more the natural adjuvant sorbitol of plant origin, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant pregelatinized Starch of plant origin, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.
4, the medicine of treatment cardiovascular disease as claimed in claim 3, it is characterized in that it is to be made by 0.8～1.2 part of breviscapine, 2.3～15 parts of adjuvants, filler adjuvant wherein is selected from following one or more the natural adjuvant sorbitol of plant origin, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant pregelatinized Starch of plant origin, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.
5, the medicine of treatment cardiovascular disease as claimed in claim 4, it is characterized in that it is to be made by 1 part of breviscapine, 3～10 parts of adjuvants, filler adjuvant wherein is selected from following one or more the natural adjuvant sorbitol of plant origin, xylitol, lactose, maltose, and they contain the water of crystallization chemical compound; Plasticity substrate wherein is selected from following one or more the natural adjuvant pregelatinized Starch of plant origin, carboxymethyl starch, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, arabic gum, alginic acid, dextrin, cyclodextrin, agar, lactose.
6, the medicine of treatment cardiovascular disease as claimed in claim 5,1 part of breviscapine, 3～10 parts of adjuvants are made, and filler adjuvant wherein is selected from following one or more the natural adjuvant xylitol of plant origin, lactose; Plasticity substrate wherein is selected from following one or more the natural supplementary product starch of plant origin, arabic gum.
7, as the medicine of the arbitrary described treatment cardiovascular disease of claim 1～6, it is characterized in that it can also contain chemosynthesis adjuvant and animal origin adjuvant in above-mentioned dressing, wherein filler comprises phenylglycol, hexadecanol, octadecanol, sodium stearate, tristerin, tripalmitin, carbamide, polyoxyethylene monostearate, polyoxyethylene alkyl ether; Wherein plasticity substrate comprises polyvinylpyrrolidone, crospolyvinylpyrrolidone, carbomer, polyvinyl alcohol, acrylic resin, poloxamer, gelatin.
8, the medicine of treatment cardiovascular disease as claimed in claim 6 is characterized in that described adjuvant is xylitol and starch, and xylitol is 1: 0.2～1: 0.3 with the ratio of the weight of starch.
9, the medicine of treatment cardiovascular disease as claimed in claim 6 is characterized in that described adjuvant is lactose and starch, and lactose is 1: 0.2～1: 0.3 with the ratio of the weight of starch.
10, the medicine of treatment cardiovascular disease as claimed in claim 6 is characterized in that described adjuvant is xylitol and arabic gum, and the ratio of the weight of xylitol and arabic gum is 1: 0.2～1: 0.4.
11,, it is characterized in that this method comprises the steps: as the preparation method of the arbitrary described treatment cardiovascular disease medicine of claim 1～6
(a) by proportioning take by weighing each crude drug breviscapine, appropriate amount of auxiliary materials is standby;
(b) in appropriate amount of auxiliary materials, add breviscapine, fully mix, be prepared into the oral formulations that allows on the pharmaceutics according to the pharmaceutics preparation method, promptly.
12, the preparation method of treatment cardiovascular disease medicine as claimed in claim 11 is characterized in that this method comprises the steps:
(a) by proportioning take by weighing 0.2～48 part of breviscapine of each crude drug, 4.8～60 parts of adjuvants are standby;
(b) in appropriate amount of auxiliary materials, add breviscapine, fully mix, mixture is at 45～115 ℃ of heating and meltings, stir, mixing time is 1～120 minute, insulation, at 45～95 ℃ of temperature following system, dropper bore is 1.0～4.0 millimeters, splash in-20～25 ℃ liquid paraffin, methyl-silicone oil or the vegetable oil, drip and make ball, promptly.
13, the preparation method of treatment cardiovascular disease medicine as claimed in claim 12 is characterized in that this method comprises the steps:
(a) by proportioning take by weighing 0.6～1.5 part of breviscapine of each crude drug, 2.0～20 parts of adjuvants are standby;
(b) in adjuvant, add the said extracted thing, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 0～18 ℃ the liquid paraffin, methyl-silicone oil, drip and make ball, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
14, the preparation method of treatment cardiovascular disease medicine as claimed in claim 13 is characterized in that this method comprises the steps:
(a) by proportioning take by weighing 0.8～1.2 part of breviscapine of each crude drug, 2.3～15 parts of adjuvants are standby;
(b) in adjuvant, add the said extracted thing, fully mix, mixture stirs at 60～85 ℃ of heating and meltings, mixing time is 10～30 minutes, insulation is 1.1～3.5 millimeters at 60～85 ℃ of temperature following system, dropper bore, splashes in 0～18 ℃ the liquid paraffin, methyl-silicone oil, drip and make ball, liquid coolant is use up and wiped to the drop pill drop that forms, back packing to be dried, promptly.
15, the preparation method of treatment cardiovascular disease medicine as claimed in claim 14 is characterized in that this method comprises the steps:
(a) by proportioning take by weighing 1 part of breviscapine of each crude drug, 3～10 parts of adjuvants are standby;
(b) get appropriate amount of auxiliary materials, add the active component of method for preparing, fully mix, mixture is at 64 ℃ of heating and meltings, stir, mixing time is 10～30 minutes, insulation, at 64 ℃ of temperature following system, dropper bore is 1.2～2.5 millimeters, splash in 0 ℃ the methyl-silicone oil, drip and make ball, to the greatest extent and wipe liquid coolant the drop pill drop that forms, back packing to be dried, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198517A CN100548307C (en) | 2004-06-30 | 2004-06-30 | A kind of medicine for the treatment of cardiovascular and cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100198517A CN100548307C (en) | 2004-06-30 | 2004-06-30 | A kind of medicine for the treatment of cardiovascular and cerebrovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714796A true CN1714796A (en) | 2006-01-04 |
| CN100548307C CN100548307C (en) | 2009-10-14 |
Family
ID=35821158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100198517A Expired - Fee Related CN100548307C (en) | 2004-06-30 | 2004-06-30 | A kind of medicine for the treatment of cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100548307C (en) |
-
2004
- 2004-06-30 CN CNB2004100198517A patent/CN100548307C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100548307C (en) | 2009-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1626122A (en) | Medication for treating cardiovascular and cerebrovascular diseases | |
| CN1626141A (en) | Medication for relieving cough and asthma | |
| CN1626143A (en) | Medication for treating pharyngitis | |
| CN1626145A (en) | Medication for treating cough | |
| CN1714796A (en) | Medicine for treating cardiocerebral vascular diseases | |
| CN1626147A (en) | Medication for treating coronary heart disease and angina | |
| CN1626134A (en) | Medication for treating chronic rhinitis and nasal sinuitis | |
| CN1626124A (en) | Drop pills of medical broth of small bupleurum root | |
| CN1626130A (en) | Medication for treating toothache | |
| CN1626149A (en) | Medication for treating cough | |
| CN1626096A (en) | Huangyangning drop pills and preparation method | |
| CN1626142A (en) | Medication for treating coronary heart disease and angina | |
| CN1626144A (en) | Medication for treating headache | |
| CN1626138A (en) | Medication for treating coronary heart disease and angina | |
| CN1626152A (en) | Medication for treating ache | |
| CN1626146A (en) | Icy seven drop pills and preparation method | |
| CN1872044A (en) | Medication for treating coronary heart disease | |
| CN1626148A (en) | Medication for treating cardiovascular and cerebrovascular diseases | |
| CN1626132A (en) | Medication for treating obstruction of qi in the chest | |
| CN1872075A (en) | Drop pills of hemsleyadin, and preparation method | |
| CN1872318A (en) | Drop pills of oil of zedoary turmeric, and preparation method | |
| CN1872052A (en) | Drop pills of simvastatin, and preparation method | |
| CN1626139A (en) | Medication in use for bacteriostasis and antiinflammation | |
| CN1872036A (en) | Drop pills of agrimophol, and preparation method | |
| CN1626133A (en) | Medication for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Yongqiang Inventor after: Wei Feng Inventor after: Chen Jianming Inventor after: Zhu Guoguang Inventor after: Zheng Yongfeng Inventor after: Zhu Yonghong Inventor after: Li Xu Inventor after: Zhang Shunnan Inventor after: Liu Jinping Inventor after: Ye Zhengliang Inventor before: Li Yongqiang Inventor before: Wei Feng Inventor before: Chen Jianming Inventor before: Zhu Guoguang Inventor before: Zheng Yongfeng Inventor before: Zhu Yonghong Inventor before: Li Xu Inventor before: Zhang Shunnan Inventor before: Liu Jinping Inventor before: Ye Zhengliang |
|
| CB03 | Change of inventor or designer information | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091014 Termination date: 20190630 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |